A growing school of thought within artificial intelligence suggests that the long-term competitive advantage in AI may no longer reside primarily in the models themselves. As advanced AI systems increasingly achieve similar capabilities, many experts believe that the true source of differentiation is shifting toward the proprietary, structured data that these models use for reasoning and decision-making. Operating from this perspective,

MindWalk Holdings Corp., a company focused on Bio-Native AI, has submitted a European patent application aimed at protecting the high-dimensional biological data structures that underpin its HYFT platform.

Key Highlights

Moving Beyond the AI Model
The central premise behind MindWalk's patent strategy is that AI models themselves are becoming increasingly interchangeable. As leading models continue to converge in capability, the company believes that enduring value will come from proprietary biological context and structured knowledge representations rather than from the models alone.

In June 2026, the Austin-based company announced the filing of European patent application EP26187897.9. The application targets high-dimensional representations of biological subsequences and associated property inference methodologies. Specifically, the filing aims to protect the enriched biological architecture that supports HYFT Technology, the ReefIQ biological context layer, and the LensAI reasoning environment.

According to Jennifer Bath, Ph.D., President and Chief Executive Officer of MindWalk, the long-term question in AI is not which model is being used, but rather the quality and structure of the biological information upon which the model operates. She argues that within life sciences, the differentiating factor is the underlying biological representation system that enables AI models and autonomous workflows to retrieve connected evidence, preserve provenance, and leverage accumulated knowledge across multiple research programs.

MindWalk positions its filing against a broader trend emerging in scientific AI: powerful models alone are insufficient for solving complex biological problems. The company points to publicly disclosed initiatives such as NVIDIA's BioNeMo Agent Toolkit and AstraZeneca's ChatInvent platform as examples demonstrating the importance of domain-specific knowledge, structured interfaces, provenance tracking, memory systems, and validation mechanisms in scientific AI applications.

Extending the Existing Foundation
The newly filed patent builds upon MindWalk's foundational HYFT patent (WO 2020/161344), which established a methodology for identifying recurring biological patterns across living systems and using those patterns as a searchable language for sequence comparison without traditional alignment methods.

MindWalk states that the new application protects a separate and complementary computational layer that organizes biological meaning around those recurring patterns. This layer is intended to enable reuse across the company's internal systems, customer programs, and AI-driven workflows. Rather than replacing the original patent, the company describes the new filing as protecting an additional architectural component built atop the existing foundation.

The distinction between this approach and purely model-centric AI systems forms a key part of MindWalk's thesis. While large language models can capture extensive knowledge, much of that information remains embedded within model parameters, making it difficult to inspect, update, or govern in regulated scientific environments.

MindWalk's architecture seeks to address this challenge by maintaining a biology-aware representation layer that connects meaningful biological patterns with associated sequence information, structural characteristics, physicochemical properties, functional annotations, experimental results, and literature-derived evidence. This information can then be retrieved, updated, compared, and reused as scientific knowledge evolves, without requiring complete retraining of underlying AI models.

Addressing Fragmented Biological Data
One of the persistent challenges in pharmaceutical discovery is the fragmentation of scientific information. A single research program may generate sequence data, structural analyses, physicochemical measurements, experimental results, literature references, and historical decision records that become distributed across numerous databases, teams, and software environments.

MindWalk argues that such fragmentation causes both researchers and AI systems to lose valuable contextual relationships. The company's proposed architecture is designed to preserve those relationships by maintaining links between biologically meaningful patterns and the contextual information explaining their significance.

According to Dirk Van Hyfte, M.D., Ph.D., Chief Technology Officer of MindWalk, biological understanding cannot be isolated into a single data format. Instead, sequence information, structure, function, physicochemical behavior, supporting evidence, and scientific literature must remain interconnected if AI systems are to generate meaningful insights. The company states that its patent filing aims to protect precisely this organizational framework.

Applying the Architecture to Research Programs
MindWalk reports that it has begun applying its approach within active research programs, although all results disclosed to date remain preclinical.

In dengue research, the company has reported binding-level preclinical data showing that targets identified through HYFT informed immunogen design efforts that produced antibodies capable of binding antigens from all four dengue virus serotypes across two separate studies.

Similarly, in influenza research, MindWalk has identified a functional constraint through HYFT analysis that appears across extensive influenza A and B datasets, including human, avian, swine-associated, Victoria, and Yamagata strains.

The company emphasizes that these findings remain preliminary and that substantial additional work will be required to evaluate factors such as neutralization efficacy, safety, durability, regulatory feasibility, clinical translation, and commercial viability.

This research strategy reflects what MindWalk describes as its functional and evolutionary constraint hypothesis: the idea that recurring biological patterns persist because they serve important roles related to structure, function, binding interactions, immune recognition, or evolutionary fitness. By preserving both the patterns and their surrounding context, the company aims to provide AI systems with a more transparent and biologically grounded reasoning framework.

Commercial Implications and Investor Perspective
MindWalk's commercial implementation of this strategy is embodied in its ReefIQ and LensAI platforms. The company reports that LensAI currently operates under recurring commercial agreements with life sciences customers and that the patent filing seeks to protect the foundational layer supporting those deployments as biological data and customer experience continue to accumulate.

Within the company's architecture, HYFT identifies biologically meaningful pattern anchors, ReefIQ organizes biological and customer data around those anchors within a governed context layer, and LensAI performs reasoning tasks that support target identification, candidate evaluation, hypothesis generation, and portfolio decision-making.

MindWalk believes this approach addresses a rapidly expanding market opportunity. Based on third-party industry projections cited by the company, spending on AI technologies for drug discovery could grow from approximately US$5 billion in 2026 to more than US$8 billion by 2030, complementing the pharmaceutical industry's annual research and development expenditures exceeding US$250 billion. The company notes that these figures represent external forecasts and are subject to uncertainty.

From an investment perspective, MindWalk presents the patent filing as part of a broader strategy to build value independent of any individual AI model. The company argues that its biology-aware representation layer constitutes a model-agnostic infrastructure asset whose value may increase as additional programs, datasets, and customer relationships become integrated into the system.

Broader Industry Context
MindWalk positions itself as a Bio-Native AI infrastructure company and emphasizes that comparisons with other public companies serve only as industry context.

Absci represents an approach centered on combining generative AI with synthetic biology and high-throughput laboratory validation for antibody discovery.

Certara operates within the biosimulation and model-informed drug development software market, providing a perspective on the established software infrastructure supporting pharmaceutical research.

AstraZeneca exemplifies the pharmaceutical industry's adoption of agentic AI systems within real-world discovery environments, including initiatives such as ChatInvent.

NVIDIA supplies much of the computational infrastructure and software ecosystem that powers contemporary AI applications, including tools designed specifically for life sciences research.

While these companies occupy different positions within the ecosystem, together they illustrate the breadth of technological approaches shaping AI-enabled drug discovery.

Conclusion
Filing a patent application represents the beginning of a process rather than a guarantee of protection. European patent examination may ultimately narrow, modify, or reject claims, and the eventual scope, enforceability, and commercial value of any granted patent remain uncertain. MindWalk itself acknowledges these risks, as well as the early-stage nature of its dengue and influenza programs.

Nevertheless, the company's strategic thesis remains clear: as AI models become increasingly commoditized, lasting competitive advantage in life sciences AI may derive from the structured biological knowledge systems that support those models. Through this filing, MindWalk is seeking to secure intellectual property protection around its own interpretation of that foundational layer.

For investors interested in identifying where durable value creation may occur as the AI ecosystem evolves, MindWalk's patent filing provides a noteworthy indicator. The ultimate significance of this strategy will likely depend on future patent outcomes, commercial adoption, and the company's ability to generate sustained revenue growth.

The San Diego Zoo is internationally renowned for its commitment to wildlife conservation and is home to the largest population of koalas outside of Australia. One significant challenge facing their koala community is the prevalence of koala retrovirus (KoRV), which is associated with various fatal conditions such as susceptibility to bacterial infections, leukemia, lymphoma, and other cancers. Surprisingly, 100% of koalas in North America, as well as those in the Australian states of Queensland and New South Wales, carry this virus. Even in Victoria, between 15% and 70% of koalas are affected.
 
The unique aspect of KoRV lies in its transmission. Unlike common horizontally transmitted viruses that infect organisms through infection, KoRV can become endogenous by integrating its genetic code into an organism's germline (reproductive) cells, such as sperm or eggs. This integration results in the viral DNA becoming a permanent part of the host's genome, transmitted vertically from one generation to the next.
 
While this may sound alarming, the presence of retroviral DNA in living organisms is not uncommon. In fact, all living organisms have accumulated retroviral DNA as a natural part of their genetic makeup. In most species, these viral integrations occurred millions of years ago, and the DNA has degraded to a point where it no longer poses a threat of infecting other hosts or causing health problems. This natural process ensures the elimination of viruses that could harm their hosts.
 
Despite this common occurrence, there is still much to learn about the transition of a retrovirus from being exogenous to becoming a relatively harmless part of a host's genome. The details of how the virus changes, if at all, during this transition and how it adapts to the host remain unknown. Researchers, such as Alex Greenwood from the Leibniz Institute for Zoo and Wildlife Research and Rachael Tarlinton from the University of Nottingham, emphasize the need to understand this process better, as some retroviruses may even be beneficial to their hosts by influencing gene expression and introducing new genetic diversity. However, the specific mechanisms and timelines of these changes remain elusive.
 
Koalas face potential threats due to the Koala Retrovirus (KoRV), a relatively recent phenomenon that began about 50,000 years ago in evolutionary terms. Unlike KoRV subtype A, which has become endogenous in koalas, subtypes B, C, and others remain exogenous, contributing to serious health issues. The San Diego Zoo has adapted its care and breeding practices to prevent the spread of these exogenous subtypes.
 
Utilizing the fact that koalas are naturally solitary and sleep extensively, the zoo manages genetic diversity through meticulous record-keeping of mean kinship. Female koalas are introduced to suitable males one at a time to control breeding. While they can have eight to 10 offspring during their 12 to 14-year lifespan, infertility due to chlamydia is a concern among wild koalas. The zoo's vigilant breeding management has successfully kept their population free of this infection.
 
Despite these efforts, koalas remain highly susceptible to cancer, which often progresses rapidly and is challenging to treat once detected. KoRV is linked to these health issues, although more genomic research is needed to establish a definitive connection. The iConserve koala retrovirus sequencing project, initiated in 2023, aims to address this gap by conducting longitudinal studies across multiple koala generations.
 
The San Diego Zoo's extensive genetic samples, spanning five generations and dating back to the 1970s, provide valuable data for the project. Illumina performed whole-genome sequencing on these samples, creating the largest pedigree of any koala genomic database to date. The information gathered through this project is expected to shed light on the genetic causation of koala health conditions, facilitating better management and conservation strategies for these iconic marsupials.

The research aims to correlate known causes of death in the zoo's pedigree with KoRV integration patterns identified in the sequencing data. This comparison will help determine the strength of the association between specific integration sites and adverse health outcomes in koalas. For instance, if certain KoRV integration patterns are linked to specific cancers in past koalas, it may enable predictions about which koalas in the future are at a higher risk of developing these cancers. Such insights are crucial for wildlife care specialists when planning optimal breeding pairs.
 
The findings from this study will not only guide breeding decisions within the zoo but will also influence management strategies for wild koala populations. With their natural habitat facing significant fragmentation, exacerbated by recent bushfires in Australia, disconnected koala populations experience reduced genetic diversity and increased vulnerability to diseases. Conservation efforts may involve strategically translocating specific animals to enhance genetic diversity and avoid introducing new KoRV subtypes to previously unaffected populations.
 
The potential discovery of associations between retroviral integration sites and immunological genes holds great promise for research. Understanding the mechanisms of KoRV endogenization and its impact on disease development is particularly intriguing given the rarity of such a virus undergoing this process. This knowledge could significantly contribute to koala health and play a vital role in their conservation efforts.
 
The scientific community has debated the intervention in the gradual and likely inevitable process of KoRV endogenization, considering the prevalence of retroviral DNA in animal genomes. However, participants in the iConserve study acknowledge a collective responsibility in this case, recognizing the importance of understanding and addressing the implications of KoRV endogenization for the well-being and conservation of koalas.

“Yes, it is a natural process,” said Higgins, “but it’s going on in an unnatural environment and context that humans are causing. It’s up to us to create an environment where that natural process can unfold. From an evolutionary perspective, it’s hard to adapt to something if you’ve got all these other pressures. We’re identifying which populations are most at risk and focusing on removing other risks to allow them to cope.”

“Over time, we expect the koala to adapt to this endogenizing virus. Until this happens, koalas are threatened by KoRV as well as by habitat loss and fragmentation. We can’t eliminate KoRV from koalas, but we can preserve and protect the healthy ecosystems that they need to survive,” said Singleton.

At the time of this update, the sequencing phase of the project has concluded, and Guilherme Neumann, a postdoctoral bioinformatician at the Leibniz Institute, has successfully identified over 1500 KoRV insertions within the 91 sequenced animals.

As anticipated for a relatively small zoo population, these koalas exhibit a higher degree of shared KoRV integration sites compared to their counterparts in the wild. According to Greenwood, the next intriguing phase will involve determining if these shared integrations predominantly occur in genome regions with minimal harm. If so, the focus will shift to the less widely shared integrations, which might harbor more problematic KoRV integrations. These specific sites could become potential targets for future management strategies.
 
Simultaneously, Singleton expresses optimism about the potential transformative impact of this research on koala conservation efforts.
 
“We’ve known for many years that we have something really special in the data from the North American koala population, but we haven’t been able to access the technology to analyze it,” she says. “Through our partnership with Illumina, we are achieving research objectives that seemed unreachable back in 2021. Bringing together this international team, learning from our koala population to help koalas in their native range, is a career pinnacle for me as a zoo veterinarian.”